Cardiol Therapeutics, Inc.

Canaccord Genuity Acted as a Lead Left Bookrunner in a Confidentially Marketed Public Offering for Cardiol Therapeutics

Canaccord Genuity is pleased to announce that on November 3, 2021, Cardiol Therapeutics, Inc. (the “Company”) (Nasdaq:CRDL), priced its $50.2 million confidentially marketed public offering at a price of $3.07 per unit. The Company issued 16,350,000 shares of common stock. Each Unit will consist of one Class A common share in the capital of the Corporation (each, a "Unit Share") and one-half Class A common share purchase warrant of the Corporation (each whole Class A common share purchase warrant, a "Warrant"). Each Warrant will entitle the holder thereof to purchase one Class A common share of the Company (each, a “Warrant Share”) at a price of US$3.75 per Warrant Share, subject to adjustment in certain events, for a period of 36 months following the closing date of the Offering.

Canaccord Genuity acted as Lead Left Bookrunner for the offering.

Cardiol Therapeutics Inc. is a clinical-stage biotechnology company focused on the research and clinical development of anti-inflammatory therapies for the treatment of CVD.